Swissmedic 更新平行进口人用药品指南,明确出口国定义与包装要求并于 2026 年 10 月 1 日生效
Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”
Swissmedic 更新了按 TPA 第 14 条第 2、3 款平行进口人用药品的指南文件,修订版自 2026 年 10 月 1 日起生效。出口国定义得到细化,一般指签发该平行进口产品国家上市许可且药品监管等效的国家,按欧盟集中程序(CP)批准的则以采购包装的欧盟国家为出口国,多国包装可标注“EU”。
修订明确了出口国定义,并调整初级、次级包装与产品信息要求,可供对照核对平行进口产品的申报细节。
Changes to the Guidance document “Import of a human medicinal product according to Art. 14 para. 2 and 3 TPA (parallel import)”
Swissmedic has updated the Guidance document on parallel imports. In particular, the changes concern clarifications on country of export, additions to the requirements for packaging, storage instructions and information on handling in the medicinal product information for parallel imported medicinal products
01.10.2026
The term “country of export” is defined in more detail under “Definitions”. In general, the country of export is the country in which the national authorisation of the parallel imported product was issued and which has equivalent medicinal product control. For authorisations according to the EU Centralised Procedure (CP), the country of export is the EU country from which the packs of the parallel imported medicinal product are procured. “EU” can be given as the country of export for multi-country packs of medicinal products authorised according to the EU CP.
The section on primary packaging requirements now stipulates that Swissmedic does not accept affixing of additional labels to existing foreign primary packaging, for example to provide translations of information into the official Swiss languages. This applies irrespective of the primary packaging type and material and of which areas of the primary packaging are to be covered by the affixed label.
The section on secondary packaging requirements has been amended to add that the statement on excipient composition, storage instructions and information on handling should be as stated on the foreign packaging. Relevant disclaimers should be placed on the secondary packaging.
In addition, the requirements for the “Other information” section in the Information for healthcare professionals and Patient information have been clarified. The text must be identical in all respects to that for the original medicinal product, with the exception of the storage instructions, information on handling and statement of known deviations from the original medicinal product. The relevant disclaimers must be used in the Information for healthcare professionals and Patient information.
The Guidance document also includes editorial corrections and additional examples.
The revised Guidance document on parallel imports is valid with effect from 1 October 2026.
来源:Swissmedic 药品质量与 GMP 更新 · swissmedic.ch